Filing Details

Accession Number:
0001601830-24-000068
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-03 18:31:41
Reporting Period:
2024-05-30
Accepted Time:
2024-06-03 18:31:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX Biological Products, (No Disgnostic Substances) (2836) 464099738
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1856414 Tina Marriott 41 S. Rio Grande Street
Salt Lake City UT 84101
President And Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2024-05-30 3,000 $1.06 538,457 No 4 M Direct
Class A Common Stock Disposition 2024-05-30 3,000 $8.78 535,457 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Stock Option (Right to Buy) Disposition 2024-05-30 0 $0.00 3,000 $1.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
482,000 2028-07-22 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Class A Common Stock Stock Option (Right to Buy) $8.55 2033-02-01 0 434,122 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2032-02-04 0 159,226 Direct
Class A Common Stock Stock Option (Right to Buy) $11.40 2022-02-04 2032-02-04 0 4,784 Direct
Class A Common Stock Stock Option (Right to Buy) $2.48 2030-12-30 0 150,000 Direct
Class A Common Stock Stock Option (Right to Buy) $10.09 2034-02-09 0 447,917 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2033-02-01 0 434,122 Direct
2032-02-04 0 159,226 Direct
2032-02-04 0 4,784 Direct
2030-12-30 0 150,000 Direct
2034-02-09 0 447,917 Direct
Footnotes
  1. Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023.
  2. Includes 2,224 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2024.
  3. This transaction was executed in multiple trades at prices ranging from $8.65 to $8.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
  5. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  6. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  7. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
  8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.